MedTrace Logo

ZEBinix® Retention Rate in Epilepsy in Elderly Patients

NCT04221282 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-01-09

No results posted yet for this study

Summary

The incidence of provoked and unprovoked seizures is known to increase with advancing age. Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs) that have been developed in the last ten years with a favorable safety profile. ESL is approved in Europe and the USA as adjunctive or monotherapy in adults with partial-onset seizures. Nevertheless, retrospective data in monotherapy condition in the elderly epileptic population are sparse. The aim of the ZEBRE study is to evaluate the efficacy and the safety of ESL in elderly epileptic patients (\> 65 years). The completion of this study will provide crucial information on the most appropriate ESL treatment for elderly patients suffering from partial seizures.

Conditions

  • Epilepsy
  • Aging Disorder
  • Aging
  • Epilepsy; Seizure

Interventions

DRUG

Zebinix

ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.

Sponsors & Collaborators

  • Centre Hospitalier Saint Joseph Saint Luc de Lyon

    lead OTHER

Principal Investigators

  • Adrien DIDELOT, MD, PhD · Centre Hospitalier saint Joseph St Luc

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-09-30
Completion
2020-09-30
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221282 on ClinicalTrials.gov